Mitochondrial Diseases clinical trials at UCSD
3 in progress, 2 open to eligible people
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
open to eligible people ages 18-70
SPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous (SC) administration of elamipretide as a treatment for subjects with primary mitochondrial myopathy associated with nuclear DNA mutations (nPMD).
San Diego, California and other locations
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
open to all eligible people
The North American Mitochondrial Disease Consortium (NAMDC) maintains a patient contact registry and tissue biorepository for patients with mitochondrial disorders.
San Diego, California and other locations
EPI-743 for Mitochondrial Respiratory Chain Diseases
Sorry, in progress, not accepting new patients
This study will evaluate the safety and efficacy of EPI-743 in participants with severe mitochondrial respiratory chain diseases who are considered to be within 90 days of end-of-life care.
San Diego, California and other locations
Our lead scientists for Mitochondrial Diseases research studies include Robert Naviaux, MD Richard Haas, MD PhD.
Last updated: